Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal tamoxifen for vulvovaginal atrophy symptoms and sexual function in women with breast cancer
2021-004536-28Phase 3Active
- Sponsor
- Uppsala University
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vaginal atrophy and breast cancer comparing Vaginal tamoxifen with Placebo (2 arms). Primary endpoint: Improvement in most troublesome vulvovaginal atrophy symptom. Started Sep 2021; status: active.
02
Drugs
tamoxifen
03
Conditions
vaginal atrophybreast cancer
Beyond the preview
Go deeper on 2021-004536-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004536-28.